Ozempic, weight-loss drugs probed over reports of suicidal thoughts Share via Novo Nordisk A/Ss weight-loss medications are under investigation by the European Unions drugs regulator after a small number of reports of suicidal risks were referred to the watchdog
Here are some things to keep in mind when preparing for a consultation: Compile a list of current medications, allergies, and medical history to share with Dr
Researchers analyzed 79 websites promoting compounded GLP-1 receptor agonists, such as semaglutide and tirzepatide, and uncovered critical transparency issues: Over half did not disclose that their products were not FDA-approved
Key interactions to note: insulin (additive hypoglycemia risk), sulfonylureas (similar hypoglycemia potentiation), oral contraceptives (delayed gastric emptying may reduce absorption backup contraception recommended during initiation), and narrow therapeutic index drugs like warfarin or levothyroxine (altered GI transit affects absorption kinetics)
Semaglutide is incredibly potent, and high initial doses can cause extreme nausea, vomiting, or GI distress